Screener
Solid Biosciences Inc. SLDB Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Solid Biosciences Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337935
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accounts payable | 1,139 | 467 |
| Change in operating lease liability | (1,006) | (848) |
| Accrued expenses and other liabilities | (1,442) | 1,695 |
| Net cash used in operating activities | (99,817) | (69,262) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (315) | (503) |
| Proceeds from maturities of available-for-sale securities | 146,880 | 69,000 |
| Purchases of available-for-sale securities | (235,396) | (128,777) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Solid Biosciences Inc.'s operating cash flow?
- Solid Biosciences Inc. (SLDB) reported operating cash flow of -$52.59M in Q2 2026.
- How has Solid Biosciences Inc.'s operating cash flow changed year-over-year?
- Solid Biosciences Inc.'s operating cash flow decreased by 40.6% year-over-year, from -$37.41M to -$52.59M.
- What is the long-term trend for Solid Biosciences Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Solid Biosciences Inc.'s operating cash flow has grown at a 19.1% compound annual growth rate (CAGR), from -$77.76M to -$156.29M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Solid Biosciences Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude